Malone Wealth Ventures holds 9.8% of Quantum Biopharma (QNTM)

Rhea-AI Filing Summary

Quantum Biopharma Ltd. received an amended Schedule 13G/A (Amendment No. 8) from Malone Wealth Ventures LLC reporting substantial ownership of its common stock. Malone Wealth Ventures reports beneficial ownership of 375,752 shares, representing 9.8% of the outstanding common shares.

The firm has sole power to vote 92,180 shares and sole power to dispose of 375,752 shares. The filing explains that these securities are held for clients of Malone Wealth Ventures, who have rights to dividends and sale proceeds, and states the holdings are in the ordinary course of business, not to influence control of the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 09:19 AM Learn about SEC filing dates

FAQ

What did Malone Wealth Ventures LLC report in its Schedule 13G/A for QNTM?

Malone Wealth Ventures LLC reported beneficial ownership of 375,752 shares of Quantum Biopharma common stock, representing 9.8% of the class. The firm filed this as an amended Schedule 13G/A, indicating holdings are passive and in the ordinary course of business.

How many Quantum Biopharma (QNTM) shares does Malone Wealth Ventures control?

Malone Wealth Ventures LLC reports beneficial ownership of 375,752 shares of Quantum Biopharma common stock. It has sole voting power over 92,180 shares and sole dispositive power over 375,752 shares, with no shared voting or shared dispositive power reported.

What percentage of Quantum Biopharma (QNTM) does Malone Wealth Ventures own?

Malone Wealth Ventures LLC reports owning 9.8% of Quantum Biopharma’s common stock. This percentage is based on its beneficial ownership of 375,752 shares, as disclosed in Amendment No. 8 to its Schedule 13G/A filed for the company.

Who ultimately benefits from the Quantum Biopharma (QNTM) shares held by Malone Wealth Ventures?

The filing states that clients of Malone Wealth Ventures LLC have the right to receive, or direct the receipt of, dividends and sale proceeds from the reported Quantum Biopharma shares. Collectively, these client holdings exceed five percent of the company’s outstanding common stock.

Is Malone Wealth Ventures’ stake in Quantum Biopharma (QNTM) considered passive or activist?

Malone Wealth Ventures certifies that the Quantum Biopharma securities were acquired and are held in the ordinary course of business. The firm states they were not acquired for the purpose of changing or influencing control of the issuer, consistent with a passive ownership stance.

When was the reportable event for Malone Wealth Ventures’ Quantum Biopharma (QNTM) holdings?

The Schedule 13G/A identifies 02/03/2026 as the date of the event requiring the filing. The certification is signed by Kevin M. Malone, President and CEO of Malone Wealth Ventures LLC, confirming the accuracy of the ownership information provided.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 8)

Quantum Biopharma Ltd.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

74764Y205

(CUSIP Number)

02/03/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 74764Y205

1

Names of Reporting Persons

Malone Wealth Ventures LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 92,180.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 375,752.00
8	Shared Dispositive Power

9

Aggregate Amount Beneficially Owned by Each Reporting Person

375,752.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.8 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: Les Gro

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Quantum Biopharma Ltd.
(b)	Address of issuer's principal executive offices: 55 UNIVERSITY AVENUE, SUITE 1003, 55 UNIVERSITY AVENUE, SUITE 1003, TORONTO, ONTARIO, CANADA, M5J 2H7.
Item 2.
(a)	Name of person filing: Malone Wealth Ventures LLC
(b)	Address or principal business office or, if none, residence: 9201 W State St. Ste 126 Boise, ID 83714
(c)	Citizenship: United States
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 74764Y205
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 375752
(b)	Percent of class: 9.8 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 92180
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 375752
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Clients of Malone Wealth Ventures LLC have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, the securities reported herein. Client's accumulative shares are more than 5% of the public company in this report.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Malone Wealth Ventures LLC

Signature:	Kevin M Malone
Name/Title:	President & CEO
Date:	02/03/2026